Kwan V, Bourke M J, Williams S J, Gillespie P E, Murray M A, Kaffes A J, Henriquez M S, Chan R O
Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead, Australia.
Am J Gastroenterol. 2006 Jan;101(1):58-63. doi: 10.1111/j.1572-0241.2006.00370.x.
The long-term efficacy of argon plasma coagulation (APC) in the management of gastrointestinal vascular lesions has not been evaluated in a large and well-defined series. The impact of APC on transfusion requirements and hemoglobin, and technical parameters including complications and number of treatment sessions, is assessed in this series.
Patients who underwent APC for bleeding gastrointestinal vascular lesions were identified via interrogation of an established endoscopic database, excluding patients with radiation proctitis, tumors, residual polypectomy tissue and acute ulcer bleeding. Follow-up data were collected via interview with patients and referring doctors, review of medical records, and follow-up blood tests.
One hundred patients were enrolled, males = 46, median age = 74 yr (range: 19-99 yr). Median follow-up time was 16 months (range: 4-47 months). Lesions treated were arteriovenous malformations (n = 74) and gastric antral vascular ectasia (n = 26). Fifty-three patients required transfusion. In this group, median hemoglobin improved from 66 g/L (range: 35-114) to 111 g/L (range: 55-155, p < 0.001). Median transfusion velocity fell from 2 units/month (range: 0.1-6) to 0 units/month (range: 0-4, p < 0.001). Transfusion requirement was abolished in 77%. In non-transfusion-requiring patients, median hemoglobin improved from 105 g/L (range: 58-143) to 123 g/L (range: 79-158, p < 0.001). No complications occurred.
APC is effective and safe in the management of gastrointestinal vascular lesions.
尚未在大型且明确界定的系列研究中评估氩离子凝固术(APC)治疗胃肠道血管病变的长期疗效。本系列研究评估了APC对输血需求和血红蛋白的影响,以及包括并发症和治疗次数在内的技术参数。
通过查询已建立的内镜数据库确定因胃肠道血管病变出血而接受APC治疗的患者,排除放射性直肠炎、肿瘤、残留息肉切除组织和急性溃疡出血患者。通过与患者及转诊医生访谈、查阅病历和随访血液检查收集随访数据。
共纳入100例患者,男性46例,中位年龄74岁(范围:19 - 99岁)。中位随访时间为16个月(范围:4 - 47个月)。治疗的病变包括动静脉畸形(n = 74)和胃窦血管扩张症(n = 26)。53例患者需要输血。在该组中,血红蛋白中位数从66 g/L(范围:�5 - 114)提高到111 g/L(范围:55 - 155,p < 0.001)。输血速度中位数从2单位/月(范围:0.1 - 6)降至0单位/月(范围:0 - 4,p < 0.001)。77%的患者不再需要输血。在无需输血的患者中,血红蛋白中位数从105 g/L(范围:58 - 143)提高到123 g/L(范围:79 - 158,p < 0.001)。未发生并发症。
APC治疗胃肠道血管病变有效且安全。